Forte Biosciences, Inc.
Forte Biosciences, Inc. (FBRX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
fbrx · stock forecast · 6 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 6 Wall Street analysts in the past 3 months
Buy
6 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$65.00
Consensus
$65.00
+311.7% upside
Low
$65.00
Median: $65 · Last Close: $15.79
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $15.00 | ↓ 5.00% |
1-day model range: $14.67–$15.34. Peak: $15.34 (-5.00%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | — | -34.0% |
| 2028 | — | -45.2% |
| 2029 | — | -49.9% |
| 2030 | — | -52.0% |
| 2031 | — | -53.1% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · FBRX · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-11-17 | Chardan Capital | Maintains | Buy→Buy |
| 2025-08-15 | Chardan Capital | Maintains | Buy→Buy |
| 2025-06-24 | Chardan Capital | Maintains | Buy→Buy |
| 2025-04-01 | Chardan Capital | Maintains | Buy→Buy |
| 2024-12-04 | Chardan Capital | Maintains | Buy→Buy |
| 2024-11-15 | Chardan Capital | Maintains | Buy→Buy |
| 2024-08-19 | Chardan Capital | Maintains | Buy→Buy |
| 2024-04-08 | Ladenburg Thalmann | Upgrade ↑ | Neutral→Buy |
| 2021-09-20 | Chardan Capital | Upgrade ↑ | Sell→Neutral |
| 2021-09-03 | Brookline Capital | Downgrade ↓ | Buy→Hold |
Wall Street analysts have recently issued updated ratings on Forte Biosciences, Inc. (FBRX) stock. Of the recent 23 rating actions, 3 were upgrades and 5 were downgrades. 6 analysts currently cover FBRX.
Analyst Recommendation Trends
FBRX analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$9M
↓ 37.1% YoY
Revenue Next Year
$23M
↑ 150.0% YoY
EPS This Year
$-4.11
EPS Next Year
$-4.25
↑ 3.6% YoY
EPS ForecastReported vs Estimated
Analysts forecast FBRX EPS of $-4.11 for the current fiscal year, based on estimates from 4 analysts. The FBRX revenue forecast is $9M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The FBRX stock forecast is supported by two independent data sources: analyst consensus ratings from 6 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus FBRX price target is $65.00 (+311.7% upside), with an analyst consensus of Buy.
The FBRX short-term stock prediction for tomorrow is $15.00 (-5.00%). The FBRX stock prediction for 2030 projects a range of $7–$8.
Forte Biosciences, Inc. trades on NASDAQ under the ticker FBRX. The FBRX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 50% of covering analysts.
Frequently asked questions
FBRX forecast · 8 questionsAccording to 6 Wall Street analysts, the average 12-month FBRX price target is $65.00, with a high forecast of $65.00 and a low of $65.00. The median price target is shown in the chart above when available. This implies +311.7% potential upside from the current price of $15.79.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.